NCI advisors approve recompetition of $62 million phase II contracts program.
Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.
Advisors approve set-aside for alternative medicine “best case series.”
HHS bans tobacco from its campuses, opens national quitline, 1-800-QUITNOW.
Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.
Funding opportunities listed.
November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
